Showing 6431-6440 of 8827 results for "".
- Tri-Luma Cream Available Againhttps://practicaldermatology.com/news/20130212-tri-luma_cream_available_again/2459616/Galderma Laboratories, L.P. recently announced that Tri-Luma® (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) Cream, the only FDA-approved triple combination topical product indicated for the short-term (up to 8 weeks) treatment of moderate to severe melasma of the face, is now avai
- Survey Data Highlight Expenses and Access-to-Care for Psoriasis Patientshttps://practicaldermatology.com/news/20130208-survey_data_highlight_expenses_and_access-to-care_for_psoriasis_patients/2459618/New findings from the National Psoriasis Foundation (NPF) indicate that patients with psoriasis and psoriatic arthritis patients spend more than $2,500 per year in out-of-pocket costs for their disease. In an analysis of eight years of data to determine access-to-care issues and out-of-pocket costs
- Merz Aesthetics Appoints New VPhttps://practicaldermatology.com/news/20130206-merz_aesthetics_appoints_new_vp/2459620/Jim Hartman has been appointed Vice President of Merz Aesthetics, Inc. Business Unit, which includes Xeomin, Radiesse, and Belotero Balance. Prior to joining Merz, Hartman was the Vice President, Global Marketing & Business Development, at Obagi Medical Products, a provider of topical skincare treat
- AADA Applauds Proposed Legislation to Repeal Medicare's IPABhttps://practicaldermatology.com/news/20130130-aada_applauds_proposed_legislation_to_repeal_medicares_ipab/2459624/The American Academy of Dermatology Association (AADA) issued a statement applauding the introduction of the Protecting Seniors' Access to Medicare Act, legislation that would repeal the Independent Payment Advisory Board (IPAB) created by the 2010 Affordable Care Act. The AADA argues that the IPAB
- Grassley Urges White House to Finish Sunshine Act Regulationshttps://practicaldermatology.com/news/20130125-grassley_urges_white_house_to_finish_sunshine_act_regulations/2459625/Sen. Chuck Grassley of Iowa today urged the White House to finalize the Physician Payments Sunshine Act regulations that will disclose the financial relationships between drug and medical device companies and doctors. “Congress designed the law so that the data would be publicly available by Sept.
- Aesyntix Partners With Sentéhttps://practicaldermatology.com/news/20130125-aesyntix_partners_with_sent/2459626/Aesyntix Physician Network (APN), a group purchasing organization and subsidiary of Aesyntix Health, Inc., entered into an agreement with Senté, Inc., a privately held cosmeceutical company that develops differentiated medical skincare pro
- Provectus Launches Free Investor Relations Apphttps://practicaldermatology.com/news/20130124-provectus_launches_free_investor_relations_app/2459627/Provectus Pharmaceuticals, Inc. launched a free mobile shareholder investor relations application. The app offers immediate portable access to the company's latest news, financial information, presentations, and factsheet. The "Provectus IR" app is a
- Study: Most Skin-Cancer Apps Unreliablehttps://practicaldermatology.com/news/20130123-study_most_skin-cancer_apps_unreliable/2459630/The University of Pittsburgh studied four smartphone apps that evaluate melanoma by analyzing images submitted by the users. One app works by having a board-certified dermatologist look at the photos, while the other three apps analyze the images by computer algorithm. The best-performing of the com
- Provectus Pharmaceuticals to Present on PV-10 at AACRhttps://practicaldermatology.com/news/20130123-provectus_pharmaceuticals_to_present_on_pv-10_at_aacr/2459631/Provectus Pharmaceuticals, Inc. will present data on PV-10 in a poster presentation at the American Association for Cancer Research Annual Meeting in Washington, DC. The PV-10 combination therapy poster, based upon an abstract entitled "Combination o
- Allergan, Inc. to Acquire MAP Pharmaceuticals, Inc.https://practicaldermatology.com/news/20130123-allergan_inc_to_acquire_map_pharmaceuticals_inc/2459632/Allergan, Inc. and MAP Pharmaceuticals, Inc. entered into a definitive merger agreement whereby Allergan will acquire 100 percent of the shares of MAP Pharmaceuticals for a price of $25.00 pe